<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775006</url>
  </required_header>
  <id_info>
    <org_study_id>NVALT 18</org_study_id>
    <nct_id>NCT02775006</nct_id>
  </id_info>
  <brief_title>Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma</brief_title>
  <official_title>A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Society of Physicians for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the effect of docetaxel monotherapy and the&#xD;
      combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK&#xD;
      negative non squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate the effect of docetaxel monotherapy and the&#xD;
      combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK&#xD;
      negative non squamous cell carcinoma.&#xD;
&#xD;
      As pemetrexed is standard first line treatment, the combination of erlotinib docetaxel in&#xD;
      non-squamous NSCLC should be investigated as second line treatment. Also the question has to&#xD;
      be answered whether the combination outperforms monotherapy treatments.&#xD;
&#xD;
      After stratification for ECOG-performance status (0-1), response to prior treatment (CR, PR,&#xD;
      SD versus PD), treatment free interval after platinum based therapy (&lt;6 months versus &gt;6&#xD;
      months) and maintenance, patients will be centrally randomized to receive either docetaxel&#xD;
      (arm A) or docetaxel plus erlotinib (arm B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    accrual to slow, target not achievable&#xD;
  </why_stopped>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>from the date of randomization to the first date of progression of disease or of death from any cause up to 24 months after last treatment administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantitative and qualitative adverse events</measure>
    <time_frame>from the date of randomization until resolution or stabilization of the event and up to 30 days after the last study medication/treatment</time_frame>
    <description>Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rates</measure>
    <time_frame>Every six weeks from date of randomization until the date of first documented progression or date of death from any cause up to 24 months after last treatment administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>from the date of the first objective status assessment of a complete or partial response to the first date of progression of disease or death from any cause up to 24 months after last treatment administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from the date of randomization to the date of death from any cause up to 24 months after last treatment administration</time_frame>
    <description>Evaluation of overall survival (OS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Erlotinib dose level variance in blood</measure>
    <time_frame>Every six weeks from randomisation up until last treatment administration (up until 48 weeks)</time_frame>
    <description>Therefore in patients on erlotinib every 6 weeks through dose levels in blood will be determined</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Carcinoma, Non-small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel plus erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_label>Docetaxel plus erlotinib</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg/day</description>
    <arm_group_label>Docetaxel plus erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed EGFR wild type, ALK negative, non-squamous&#xD;
             cell carcinoma, locally advanced and metastatic disease stage IIIB and IV. Evidence of&#xD;
             disease progression after one cytotoxic treatment platinum containing regimen.&#xD;
             Immunotherapy pretreatment is allowed&#xD;
&#xD;
          2. Complete recovery from prior chemotherapy side effects to &lt; Grade 2.&#xD;
&#xD;
          3. At least one unidimensionally measurable lesion meeting RECIST criteria.&#xD;
&#xD;
          4. ECOG PS 0-1.&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Adequate organ function, including:&#xD;
&#xD;
               -  Adequate bone marrow reserve: ANC &gt; 1.5 x 109/L, platelets ≥ 100 x 109/L.&#xD;
&#xD;
               -  Hepatic: bilirubin ≤1.5 x ULN (upper limit normal), AP, ALT, AST ≤ 1.5 x ULN. AP,&#xD;
                  ALT, and AST ≤5 x ULN is acceptable if the liver has tumor involvement.&#xD;
&#xD;
               -  Renal: calculated creatinine clearance ≥ 40 ml/min based on the Cockcroft-Gault&#xD;
                  formula.&#xD;
&#xD;
          7. Male and female patients with reproductive potential must use an approved&#xD;
             contraceptive method, if appropriate. Female patients with childbearing potential must&#xD;
             have a negative serum pregnancy test within 7 days prior to study enrollment.&#xD;
&#xD;
          8. Signed informed consent.&#xD;
&#xD;
          9. Patient compliance and geographical proximity that allow adequate follow up.&#xD;
&#xD;
         10. Patients who have undergone cranial irradiation for brain metastases more than 4 weeks&#xD;
             before inclusion in our protocol, provided that they are clinically fit to undergo&#xD;
             second line treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. Patients with medical risks because of non-malignant disease as well as those with&#xD;
             active uncontrolled infection.&#xD;
&#xD;
          3. Documented brain metastases unless the patient has completed local therapy for central&#xD;
             nervous system metastases at least 4 weeks before enrollment and has been off&#xD;
             corticosteroids for at least two weeks before enrollment. Prophylactic irradiation at&#xD;
             least 4 weeks prior to enrollment is accepted.&#xD;
&#xD;
          4. Maintenance treatment with erlotinib or other TKI (Tyrosine Kinase Inhibitor), or&#xD;
             docetaxel. Maintenance treatment with pemetrexed is allowed. Previous treatment with&#xD;
             an EGFR-TKI or docetaxel within 6 months prior to enrollment.&#xD;
&#xD;
          5. Inability or unwillingness to take dexamethasone.&#xD;
&#xD;
          6. Concomitant treatment with any other experimental drug under investigation.&#xD;
&#xD;
          7. Patients experiencing disease progression within 2 months after the start of platinum&#xD;
             based chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim G Aerts, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dutch Society of Physicians for Pulmonology and Tuberculosis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VUmc Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2130 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCL</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurentius Hospital</name>
      <address>
        <city>Roermond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Fransicus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Haaglanden</name>
      <address>
        <city>the Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

